Blood and Lymphatic Cancer: Targets and Therapy (Dec 2019)
The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma
Abstract
Catherine Lai,1 Adrese Michael Kandahari,1 Chaitra Ujjani2 1Lombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington, DC, USA; 2Seattle Cancer Care Alliance, Fred Hutchinson CRC, University of Washington, Seattle, WA, USACorrespondence: Catherine LaiLombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington, DC, USATel +1-202-444-3735Fax +1-202-444-0939Email [email protected]: The arrival of the CD30 directed antibody-drug conjugate, brentuximab vedotin (BV), has altered the approach to patients with classical Hodgkin lymphoma. Since initial approval in 2011, BV has been extensively studied in previously untreated and relapsed/refractory patients. Treatment indications for the antibody-drug conjugate have been expanded from the previously treated population to include maintenance therapy after autologous stem cell transplantation and recently, combination with chemotherapy in newly diagnosed advanced stage patients. This article will review the evolution of BV in classical Hodgkin lymphoma, detailing the studies that led to the approved indications and discussion of recent trials in combination with chemotherapy and immunotherapy.Keywords: antibody-drug conjugate, brentuximab vedotin, CD30, immunotherapy, classical Hodgkin lymphoma, novel therapies
